Instylla: An Easy, Predictable, and Simpler Way to Embolize Tumors

article image

Instylla is now enrolling patients in a clinical trial for the world’s first hydrogel-based liquid embolic intended for the treatment of hypervascular tumors. A second initial application for its Embrace embolic therapy is hemorrhage control, where the product offers advantages in terms of simplicity, speed, and safety.

Amar Sawhney and his teams, it seems, can make medical hydrogels do anything they want them to. The products of four hydrogel companies Sawhney founded with his partner Fred Khosravi (within their accelerator Incept LLC), have treated more than five million patients across the ophthalmic, surgical, interventional cardiology, and prostate cancer specialties.


This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Sign up for All-Access

Join our global community with a subscription to both MedTech Strategist and Market Pathways for one low price.



We're here to help! Please contact us at: